uniQure is delivering on the promise of gene therapy, single treatments with potentially curative results. We have developed a modular platform to rapidly bring new disease modifying therapies to patients with severe disorders. We believe our multiple partnerships and the regulatory approval of our lead product Glybera in the European Union for a subset of patients with LPLD provides validation for our approach. Home Company About uniQure Management Team Supervisory Board Platform Gene Therapy Gene Therapy Approach Disease Areas Pipeline Clinical Pipeline Glybera Clinical and Preclinical Programs Strategic Development Partners Investors Shareholder Information SEC & Financial Reports Share Information Corporate Governance Media Latest Press Releases Events Scientific Publications search Latest News Positive Topline Results Announced from Phase I/II Trial in Sanfilippo B Syndrome Patients Using uniQure’s Novel AAV5-Based Gene Therapy Sep 19, 2015 > Read More uniQure to Present at NewsMakers in the Biotech Industry Conference - NYC Sep 1, 2015 > Read More uniQure Announces Financial Results for Second Quarter 2015 Aug 27, 2015 > Read More uniQure Announces Receipt of $53 Million from Bristol-Myers Squibb for Target Selection Payment and Additional Equity Investment Aug 10, 2015 > Read More Dr. Charles W. Richard Joins uniQure as Senior Vice President to Lead Development of CNS-focused Gene Therapy Pipeline Jul 16, 2015 > Read More Careers | Contact | Disclaimer | Press | RSS Feed